Literature DB >> 12452551

Topiramate in opiate withdrawal.

Daniele F Zullino1, Anne-Claude Cottier, Jacques Besson.   

Abstract

The alpha2-adrenergic agonist clonidine is the mainly used drug for the opiate withdrawal. Its efficacy and tolerance in treating withdrawal symptoms is, however, suboptimal. The pharmacological profile of topiramate suggests it could be rather valuable for opiate withdrawal, as there is some evidence that topiramate acts, among others, through inhibition of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors, which play an important role in the withdrawal-induced activation of the locus coeruleus (LC) by glutamate. Three patients undergoing an inpatient opiate detoxification program were treated with topiramate, which achieved a nearly complete control of withdrawal symptoms.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12452551     DOI: 10.1016/s0278-5846(02)00251-8

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  10 in total

1.  Topiramate impairs cognitive function in methadone-maintained individuals with concurrent cocaine dependence.

Authors:  Olga Rass; Annie Umbricht; George E Bigelow; Eric C Strain; Matthew W Johnson; Miriam Z Mintzer
Journal:  Psychol Addict Behav       Date:  2014-11-03

2.  Effects of topiramate in combination with intravenous nicotine in overnight abstinent smokers.

Authors:  Mehmet Sofuoglu; James Poling; Maria Mouratidis; Thomas Kosten
Journal:  Psychopharmacology (Berl)       Date:  2006-01-24       Impact factor: 4.530

Review 3.  Pharmacological strategies for detoxification.

Authors:  Alison M Diaper; Fergus D Law; Jan K Melichar
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

4.  Effect of ceftriaxone and topiramate treatments on naltrexone-precipitated morphine withdrawal and glutamate receptor desensitization in the rat locus coeruleus.

Authors:  María Carmen Medrano; Aitziber Mendiguren; Joseba Pineda
Journal:  Psychopharmacology (Berl)       Date:  2015-03-20       Impact factor: 4.530

Review 5.  Topiramate in the treatment of substance-related disorders: a critical review of the literature.

Authors:  Ann K Shinn; Shelly F Greenfield
Journal:  J Clin Psychiatry       Date:  2010-03-09       Impact factor: 4.384

Review 6.  Drug deprescription-withdrawal risk, prevention, and treatment.

Authors:  Madison K Bangert; Gabriel M Aisenberg
Journal:  Proc (Bayl Univ Med Cent)       Date:  2019-12-20

Review 7.  Non-Opioid Neurotransmitter Systems that Contribute to the Opioid Withdrawal Syndrome: A Review of Preclinical and Human Evidence.

Authors:  Kelly E Dunn; Andrew S Huhn; Cecilia L Bergeria; Cassandra D Gipson; Elise M Weerts
Journal:  J Pharmacol Exp Ther       Date:  2019-08-07       Impact factor: 4.030

8.  Pregabalin abuse among opiate addicted patients.

Authors:  Martin Grosshans; Tagrid Lemenager; Christian Vollmert; Nina Kaemmerer; Rupert Schreiner; Jochen Mutschler; Xenija Wagner; Falk Kiefer; Derik Hermann
Journal:  Eur J Clin Pharmacol       Date:  2013-08-30       Impact factor: 2.953

9.  Topiramate does not alter nicotine or cocaine discrimination in rats.

Authors:  Bernard Le Foll; Zuzana Justinova; Carrie E Wertheim; Chanel Barnes; Steven R Goldberg
Journal:  Behav Pharmacol       Date:  2008-02       Impact factor: 2.293

10.  Effect of five common anticonvulsant drugs on naloxone-precipitated morphine withdrawal in mice.

Authors:  V Hajhashemi; M Abed-Natanzi
Journal:  Res Pharm Sci       Date:  2011-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.